HOME >> BIOLOGY >> NEWS
FDA grants Accentia Biopharmaceuticals...

Tampa, Fla. --Accentia Biopharmaceuticals, Inc. (Nasdaq:ABPI) has been notified that the U.S. Food and Drug Administration (FDA) granted Fast Track status to SinuNaseTM, the Company's intranasal Amphotericin B formulation. To the best of the Company's knowledge, SinuNase is the first and only drug candidate for chronic sinusitis (CS) to receive Fast Track status from the FDA.

Under the FDA Modernization Act of 1997, a new drug may be designated "Fast Track" provided the agency feels that the drug candidate has the potential to address unmet medical needs by treating serious or life-threatening conditions. With Fast Track status for SinuNase, Accentia is now eligible to submit a new drug license application (NDA) on a rolling basis, allowing the FDA to review sections of the NDA in advance of receiving Accentia's full submission, and permitting Accentia to apply for expedited review of its NDA.

Frank E. O'Donnell, Jr., M.D., Accentia's Chairman and CEO, commented: "Chronic sinusitis represents a substantial unmet clinical need, causing significant morbidity and expense. There is no approved pharmaceutical for the treatment of chronic sinusitis, despite 31 million affected patients in the U.S. alone, and about 500,000 patients who resort to sinus surgery each year in an attempt to control their chronic symptoms . These patients have chronic obstruction of the sinuses, which predisposes them to acute sinusitis, a bacterial super-infection for which more than 40 million antibiotic prescriptions are dispensed annually. The healthcare cost of chronic sinusitis is estimated at greater than $5 billion a year."

Accentia is preparing to commence its Phase 3 placebo-controlled clinical trial with SinuNase to treat post-surgical patients suffering from recurrent CS. The study is intended to be a four-month double-blinded comparison of symptomatic relief in patients randomized for treatment with either SinuNase or a placebo control.
'"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
12-Apr-2006


Page: 1 2 3 4

Related biology news :

1. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
2. New grants bolster efforts to generate faster and cheaper tools for DNA sequencing
3. New amfAR research grants to optimize HIV treatment
4. Ancient Etruscans were immigrants from Anatolia, or what is now Turkey
5. Berkeley Lab Life Sciences division awarded NIH grants for fruit fly, nematode studies
6. UAF researchers garner $6.5 million in NSF grants
7. Burroughs Wellcome fund awards $8.25 million in grants to physician-scientists
8. UCLA scientists garner 7 grants to fund leading-edge embryonic stem cell research
9. New medications, cancer diagnosis goals of UH engineers with $1M in grants
10. Barrow receives two grants worth a total of 900,000 from the ABRC
11. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/3/2020)... ... August 03, 2020 , ... ... a new partnership with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva ... strengthen their laboratory supply chain for more than 10 years. Early in the ...
(Date:7/22/2020)... ... 21, 2020 , ... USDM Life Sciences , a ... a new solution to manage regulated workloads on Microsoft Azure. , Regulated biotechnology, ... complies with FDA and global regulations. USDM's new managed service for regulated workloads ...
(Date:7/10/2020)... CHURCH, Va. (PRWEB) , ... July 08, 2020 ... ... The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July ... may need a comparability study, but what is the most effective way to ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... Modality ... for free its new white paper – Simulated Transport Methodologies. Regulatory expectations ... biologics licensing application (BLA). In response, Modality Solutions shares an explanation of ...
(Date:7/31/2020)... ... , ... R3 Stem Cell International is now offering patients the opportunity to ... total, patients may choose which extremities they would like treated. , Several studies have ... 2016). At R3 International, umbilical cord tissue is obtained from a lab with a ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been ... webinar will cover the history of eSource, the reasons it did not take off ... wearables, to site source, the industry is moving towards capturing data electronically for clinical ...
(Date:7/18/2020)... ... 16, 2020 , ... “We are thrilled to deliver this new technology to ... of its kind on the market and we were pleased that the IFT jury ... traditional cultured ingredients, creating a natural way to extend the shelf life and improve ...
Breaking Biology Technology:
Cached News: